SPOTLIGHT: S&P likes GTx's Acapodene


Standard & Poor's Equity Research says that GTx is in an enviable position. Late-stage data is due this quarter for Acapodene, an experimental therapy for prostate cancer. "We believe both target markets represent population opportunities of more than 1 million patients." Report

Suggested Articles

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.

Lilly has created customized mobile research units to run the clinical trial as the long-term care facilities lack experience running studies.